Neurogene Entered Securities Purchase Agreement For A PIPE Investment, Expected To Result In Gross Proceeds Of $200M
Neurogene Entered Securities Purchase Agreement For A PIPE Investment, Expected To Result In Gross Proceeds Of $200M
Pursuant to the terms of the securities purchase agreement, Neurogene is selling an aggregate of (i) 1,835,000 shares of its common stock ("Common Stock") at a purchase price of $50.00 per share and (ii) pre-funded warrants to purchase 2,165,042 shares of Common Stock at a price of $49.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. Following the transaction, there will be approximately 21.0 million shares of common stock outstanding (assuming the exercise in full of all pre-funded warrants). The PIPE financing is expected to close on or about November 5, 2024, subject to satisfaction of customary closing conditions.
根据证券购买协议条款，纽罗吉将以每股50.00美元的价格出售（i）183.5万股普通股（" Common Stock "）和（ii）预融资认股权证，以每张49.999美元的价格购买216.5042万股普通股。预融资认股权证的行使价格为每股0.001美元。交易完成后，假设所有预融资认股权证全部行使，普通股总股数约为2100万股。PIPE融资预计将于2024年11月5日左右结束，视具有惯常的结束条件而定。
